口服降糖药物机制及作用--培训课件.pptVIP

* CITATIONFehse F, Trautmann M, Holst JJ, et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005;90:5991-5997. SEEpg 5994 Figure 2-B (for slide data); pg 5991 “Results” and pg 5994 “Discussion” (for discussion); pg 5993 Table 1 (for background information) DISCUSSION Exenatide-treated type 2 diabetes patients had an insulin secretory pattern similar to healthy subjects in both first (0-10 min) and second (10-180 min) phases after glucose challenge compared with saline-treated pat